Stock Scorecard



Stock Summary for BioNTech SE (BNTX) - $89.67 as of 10/23/2026 3:00:10 PM EST

Total Score

9 out of 30

Safety Score

38 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BNTX

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BNTX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BNTX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BNTX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BNTX (38 out of 100)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 9
Book Value to Price (Max of 10) 1
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for BNTX

BioNTech (BNTX) and Bristol Myers Squibb plan to replace chemotherapy in a breast cancer trial, pending approval. 10/22/2026 12:10:00 PM
BioNTech plans the first global late-stage test of a cancer-drug pairing, pending approval 10/22/2026 11:11:00 AM
BofA cuts BioNTech stock target from USD 122.00 to USD 114.00 10/20/2026 6:46:00 PM
Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch 10/19/2026 1:10:00 PM
BioNTech (BNTX) will present first results for two cancer drug combinations 10/19/2026 11:10:00 AM
BioNTech Faces Setbacks in Clinical Trials Amid Pipeline Hopes 10/18/2026 8:13:00 PM
BioNTech SE Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - BNTX 10/16/2026 10:39:00 AM
BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX) 10/14/2026 7:22:00 PM
BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX) 10/14/2026 7:13:00 PM
Biontech SE Stock (BNTX) Closed Down by 7.13% on Oct 13: Drivers Behind the Movement 10/14/2026 2:43:00 AM

Financial Details for BNTX

Company Overview

Ticker BNTX
Company Name BioNTech SE
Country N/A
Description BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2026
Next Earnings Date 11/3/2026

Stock Price History

Last Day Price 89.67
Price 4 Years Ago 150.22
Last Day Price Updated 10/23/2026 3:00:10 PM EST
Last Day Volume 1,164,496
Average Daily Volume 1,027,038
52-Week High 124.00
52-Week Low 79.52
Last Price to 52 Week Low 12.76%

Valuation Measures

Trailing PE N/A
Industry PE 38.52
Sector PE 44.31
5-Year Average PE -10.57
Free Cash Flow Ratio 2.31
Industry Free Cash Flow Ratio 38.00
Sector Free Cash Flow Ratio 39.44
Current Ratio Most Recent Quarter 7.85
Total Cash Per Share 38.76
Book Value Per Share Most Recent Quarter 79.35
Price to Book Ratio 1.22
Industry Price to Book Ratio 14.03
Sector Price to Book Ratio 30.68
Price to Sales Ratio Twelve Trailing Months 8.65
Industry Price to Sales Ratio Twelve Trailing Months 20.30
Sector Price to Sales Ratio Twelve Trailing Months 23.03
Analyst Buy Ratings 13
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 251,204,000
Market Capitalization 22,525,462,680
Institutional Ownership N/A

Dividends

Ex-Dividend Date 6/2/2022
Previous Dividend Amount 0.0000
Current Dividend Amount 2.1322
Total Years Dividend Increasing 0
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 1
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -43.20%
Annual Earnings Growth -64.03%
Reported EPS 12 Trailing Months -7.83
Reported EPS Past Year -4.98
Reported EPS Prior Year -3.78
Net Income Twelve Trailing Months -1,692,286,827
Net Income Past Year -1,091,261,192
Net Income Prior Year -665,300,000
Quarterly Revenue Growth YOY -59.50%
5-Year Revenue Growth 41.71%
Operating Margin Twelve Trailing Months -807.00%

Balance Sheet

Total Cash Most Recent Quarter 9,736,978,817
Total Cash Past Year 7,672,133,311
Total Cash Prior Year 9,761,900,000
Net Cash Position Most Recent Quarter 9,478,078,817
Net Cash Position Past Year 7,456,933,311
Long Term Debt Past Year 215,200,000
Long Term Debt Prior Year 214,700,000
Total Debt Most Recent Quarter 258,900,000
Equity to Debt Ratio Past Year 0.99
Equity to Debt Ratio Most Recent Quarter 0.99
Total Stockholder Equity Past Year 19,216,018,084
Total Stockholder Equity Prior Year 19,411,100,000
Total Stockholder Equity Most Recent Quarter 17,750,169,526

Free Cash Flow

Free Cash Flow Twelve Trailing Months 518,341,726
Free Cash Flow Per Share Twelve Trailing Months 2.06
Free Cash Flow Past Year 269,813,636
Free Cash Flow Prior Year -244,600,000

Options

Put/Call Ratio 0.80
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta 1.25
RSI 0.00
50-Day SMA 99.60
150-Day SMA 100.98
200-Day SMA 108.17

System

Modified 10/23/2026 7:34:33 PM EST